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Abstract
Acquired pure megakaryocytic aplasia is a rare hematological disorder characterized by thrombocyto-
penia with absent or markedly reduced megakaryocytes in the bone marrow. We report a case of a 
25-year-old male diagnosed as acquired pure megakaryocytic aplasia. Treatment with prednisone and 
intravenous immunoglobulin failed, but he was successfully treated with cyclosporine, with complete 
remission after 90 days and normal platelet count maintained thereafter. 
(Turk J Hematol 2010; 27: 289-93)
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Özet
Kazan×lm×ü saf megakaryositik aplazi, kemik iliùinde namevcut ya da anlaml× ölçüde azalt×lm×ü mega-
karyosit içeren trombositopeni ile karakterize, nadir hematolojik bir hastal×kt×r. Kazan×lm×ü saf mega-
karyositik aplazi teühisi konmuü, prednizon ve intravenöz immunoglobulin ile tedavisi baüar×s×z olmuü 
ve siklosporin ile baüar×l× biçimde tedavi edilerek 90 gün sonra tam remisyona ulaüan ve ondan sonra 
platelet say×m× normalleüen 25 yaü×nda erkek bir olgunun raporu sunulmuütur. 
(Turk J Hematol 2010; 27: 289-93 )
Anahtar kelimeler: Kazan×lm×ü amegakaryositik trombositopeni, steroidler, siklosporin
Geliü tarihi: 27 May×s 2009   Kabul tarihi: 31 Temmuz 2009Introduction
Megakaryocytic aplasia, especially acquired pure 
megakaryocytic aplasia (APMA), is a rare hemato-
logic disorder. APMA  is characterized by severe 
thrombocytopenia resulting from marked decrease 
or absence of megakaryocytes in the marrow in the 
presence of otherwise normal erythropoiesis and 
granulopoiesis. APMA can be either idiopathic or 
caused by a variety of conditions, such as acquired 
clonal cytogenetic abnormalities, drug sensitivity, 
toxin exposure, infectious diseases such as viral 
infection [1,2], immune diseases such as lupus ery-
thematosus [3], systemic sclerosis [4], eosinophilic 
fasciitis [5], and malignancy [6,7]. Patients with 
acquired amegakaryocytic thrombocytopenia may 
have additional hematological abnormalities such 
as macrocytosis or dyserythropoiesis, abnormalities 
which may indicate potential future progression to 
aplastic anemia or myelodysplasia [8-10].
Case Report
A 25-year-old male from Nepal presented in 
August 2008 with a one-week history of headache, 
gum bleeding and epistaxis. There was no history of 
trauma, arthralgia, weight loss, drug intake, alcohol 
consumption, or fever and no family history of 
bleeding diathesis. He was not known to have any 
chronic disease. Physical examination showed mul-
tiple ecchymoses and petechiae all over the body 
with bilateral retinal hemorrhage. He had no hepa-
tosplenomegaly or lymphadenopathy.
Complete blood count showed white blood cells 
(WBC) 9.7x109/L with normal differential, hemoglo-
bin (Hb) 9.1 g/dl, mean corpuscular volume (MCV) 
102 fl, reticulocytes 7.2% (total 210x109/L), and 
platelet (PLT) count 5x109/L. Peripheral blood 
smears revealed normochromic normocytic red 
cells with polychromasia and markedly decreased 
PLT. Direct and indirect Coombs tests were nega-
tive; prothrombin time, partial thromboplastin time, 
liver and renal function tests, serum iron, transferrin 
saturation, serum B12, red cells, and serum folate 
were all normal. Autoimmune screen including 
anticardiolipin, antinuclear antibodies, rheumatoid 
factor, and C3 and C4 were negative. Serological 
markers for infections like hepatitis virus (A, B & C) 
and antibodies against human immunodeficiency 
virus (HIV), rubella, cytomegalovirus, varicella, her-
pes simplex virus types 1& 2, Epstein-Barr virus 
(EBV) and Toxoplasma gondii were all negative; 
serological test for parvovirus B19 was not done. 
The magnetic resonance imaging (MRI) of the 
brain showed multiple subcentrimetric foci of hem-
orrhagic lesions in the left and right parietal regions 
and in the frontal region. Computed tomography 
scan of the chest, abdomen and pelvis was normal.
Bone marrow aspiration revealed complete 
absence of megakaryocytes in an otherwise normo-
cellular marrow with active erythro- and granulo-
poiesis, with no dysplastic features or abnormal cell 
infiltrates. Iron stores were depleted. The histology 
of the biopsy and immunohistochemistry using 
CD61 antibody (GPIIIa) confirmed the isolated 
megakaryocytic aplasia (Figure 1). Cytogenetic 
analysis of the bone marrow showed a normal male 
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Figure 1. A. Peripheral smear showing severe thrombocytopenia (Wright stain X1000). B: Bone marrow biopsy shows mixed cellular 
hemopoietic cells with absent megakaryocytes before treatment (H&E stain X400)
A Bkaryotype. Based on the clinical and laboratory 
results, a diagnosis of APMA was made.
In view of the widespread hemorrhage and MRI 
findings, the patient was treated initially with PLT 
transfusion and methylprednisolone 5 mg/kg/day 
intravenous (IV) for 3 days followed by oral dose of 
prednisone 1 mg/kg/day that was continued for 2 
weeks and then tapered over 4 weeks until discon-
tinuation. On Day 5 of steroid, no response was 
obtained, so empirical intravenous immunoglobu-
lin (IVIG) 1 g/kg/day for 2 days was added, but 
again no significant response was achieved. Oral 
cyclosporine 5 mg/kg/day was started on Day 12 of 
treatment, and 2 weeks later the PLT count began 
to rise and transfusions were no longer required. 
The patient was discharged with a PLT count of 
60x109/L and was followed as an outpatient. Three 
months later, complete blood count normalized, 
PLT count was 148x109/L with Hb of 14 g/dl, and 
the bone marrow follow-up was cellular with a 
good number of megakaryocytes and well-repre-
sented erythropoiesis and granulopoiesis (Figure 2). 
The patient is currently under follow-up with main-
tenance of a normal PLT count (Figure 3) on the 
same dose of cyclosporine, with satisfactory thera-
peutic levels and normal renal function. The plan 
is to continue cyclosporine for up to one year with 
gradual tapering of the dose before stopping. 
Waiver consent is available at Hamad Medical 
Corporation Research office.
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Figure 3. Clinical course with treatment given and changes in platelet count
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Figure 2. A. Peripheral smear after treatment with cyclosporine (after 3 months) showing normalization of the platelet count (Wright stain 
X1000). B: Bone marrow biopsy shows active marrow with adequate number of megakaryocytes (H&E X400)
ABDiscussion
Isolated thrombocytopenia and megakaryocytic 
aplasia, inconsistently described as APMA or 
acquired amegakaryocytic thrombocytopenia pur-
pura (AATP), is a rare disease in the field of hema-
tology. The exact prevalence is unknown and the 
available literature comprises case reports and 
small case series. It is possible that the incidence 
rate is higher than what is reported and that many 
of the cases are underdiagnosed or misdiagnosed 
as immune thrombocytopenia [10]. The clinical 
course of this rare disease seems to be variable. In 
some patients, it progresses rapidly to aplastic ane-
mia [8] or myelodysplasia [9]. The usual clinical 
presentation of APMA is with bruising and bleeding 
with the absence of splenomegaly. 
The exact pathogenesis behind this disease is 
still uncertain; several studies suggest an immune–
mediated process. Benedetti et al. [11] showed 
cell-mediated immunosuppression of megakaryo-
cytes by demonstrating a marked increase in 
T-activated suppressor cells (CD8+/DR+) in asso-
ciation with AATP . A role for humoral immunity was 
also proposed in the pathogenesis of AATP when 
Katai et al. [12] showed significant suppression of 
megakaryocyte colony formation of normal marrow 
cells with the addition of AATP patient serum to 
marrow cultures. Antibodies against thrombopoi-
etin have been described to cause this disorder 
[13], as have antibodies against the TPO receptor, 
the c-mpl [3,14]. Chromium-tagged survival studies 
in patients with APMA have shown normal results, 
ruling out PLT destruction or sequestration [15].
Due in part to the heterogeneous nature of the 
syndrome and the variety of the pathogenic mech-
anisms, no standard treatment has been estab-
lished; however, several empirical therapies are 
used in patients with AATP and include the admin-
istration of corticosteroids , IVIG, cyclophospha-
mide, vincristine, cyclosporine, anti-thymocyte 
globulin (ATG), splenectomy [15-18], allogenic 
bone marrow transplantation [19], and recently, 
mycophenolate mofetil [20].
The administration of corticosteroids, IVIG, cyclo-
phosphamide, vincristine, androgens, and myco-
phenolate mofetil are transiently effective in occa-
sional patients with AATP [1,15,16,20]; however, the 
administration of cyclosporine alone or in combina-
tion with ATG was shown to be very effective in the 
treatment of AATP [10,15,17,18].
Our patient represents a typical case of APMA 
with severe thrombocytopenia and absent marrow 
megakaryocytes. Predictors that indicate the dis-
ease progression such as clonal cytogenetic abnor-
malities, macrocytosis or dyserythropoiesis were 
not present; the anemia was explained by the sig-
nificant mucocutaneous bleeding or autoimmune 
mechanism. No obvious cause of the APMA could 
be found in this patient. There was no history of 
exposure to chemicals or drugs, and clinical exami-
nation and investigations excluded collagen dis-
eases, infections, malignancies, and congenital 
anomalies like absent radius. Unfortunately, tests 
for TPO and c-MpI antibodies are not available in 
our center.
The response to immunosuppressive treatments, 
especially the cyclosporine, would suggest an 
immune-mediated pathogenetic mechanism. 
Normalization of the PLT count was achieved 90 
days after the start of treatment. As of the prepara-
tion of this report, the patient is well, with a PLT 
count of 198x109/L and Hb of 14 g/dl, maintained on 
5 mg/kg/day cyclosporine (for 7 months from the 
initiation of treatment), with continuing monitoring 
to ensure response and to detect any progression to 
aplastic anemia or myelodysplastic syndrome.
In conclusion, this case report supports the effec-
tiveness of cyclosporine at the prescribed dose of 5 
mg/kg/day in the management of APMA.
Conflict of Interest
No author of this paper has a conflict of interest, 
including specific financial interests, relationships, 
and/or affiliations relevant to the subject matter or 
materials included in this manuscript.
References
1.  Felderbauer P , Ritter PR, Mattern D, Schmitz F, Bulut K, 
Ansorge N, Schmitt-Graeff A, Schmidt WE, Baier JE. 
Acquired pure megakaryocytic aplasia: a separate 
haematological disease entity or a syndrome with mul-
tiple causes? Eur J Haematol 2004;72:451-4.
2.  Bhattacharyya J, Kumar R, Tyagi S, Kishore J, Mahapatra 
M, Choudhry VP . Human parvovirus B19-induced 
acquired pure amegakaryocytic thrombocytopenia. Br 
J Haematol 2005;128:128-9.
3.  Kuwana M, Kaburaki J, Okazaki Y, Miyazaki H, Ikeda Y. 
Two types of autoantibody-mediated thrombocytope-
nia in patients with systemic lupus erythematosus. 
Rheumatology (Oxford) 2006;45:851-4.
Omri et al.
Acquired amegakaryocytic thrombocytopenia treated with cyclosporine Turk J Hematol 2010; 27: 289-93 2924.  Katsumata Y, Suzuki T, Kuwana M, Hattori Y, Akizuki S, 
Sugiura H, Matsuoka Y. Anti-c-Mpl (thrombopoietin 
receptor) autoantibody-induced amegakaryocytic 
thrombocytopenia in a patient with systemic sclerosis. 
Arthritis Rheum 2003;48:1647-51.
5.  Chaudhary UB, Eberwine SF, Hege KM. Acquired 
amegakaryocytic thrombocytopenia purpura and 
eosinophilic fasciitis: a long relapsing and remitting 
course. Am J Hematol 2004;75:146-50.
6.  Maslovsky I, Gefel D, Uriev L, Ben Dor D, Lugassy G. 
Malignant thymoma complicated by amegakaryocytic 
thrombocytopenic purpura. Eur J Intern Med 
2005;16:523-4.
7.  Lai DW, Loughran TP Jr, Maciejewski JP , Sasu S, Song 
SX, Epling-Burnette PK, Paquette RL. Acquired amega-
karyocytic thrombocytopenia and pure red cell aplasia 
associated with occult large granular lymphocyte leu-
kemia. Leuk Res 2008;32:823-7.
8.  King JA, Elkhalifa MY, Latour LF. Rapid progression of 
acquired amegakaryocytic thrombocytopenia to aplas-
tic anemia. Southern Med J 1997;90:91-4.
9.  Erkurt MA, Kaya E, Baran M, Yitmen E, Snel S, Kuku I, 
Aydogdu I. Rapid progression of acquired amega-
karyocytic thrombocytopenia to myelodysplastic syn-
drome: case report. Turk J Haematol 2005;22:205-8.
10.  Niparuck P , Atichatakarn V, Chuncharunee S. Successful 
treatment of acquired amegakaryocytic thrombocyto-
penic purpura refractory to corticosteroids and intrave-
nous immunoglobulin with antithymocyte globulin 
and cyclosporin. Int J Hematol 2008;88:223-6.
11.  Benedetti F, de Sabata D, Perona G. T suppressor acti-
vated lymphocytes (CD8+/DR+) inhibit megakaryo-
cyte progenitor cell differentiation in a case of acquired 
amegakaryocytic thrombocytopenic purpura. Stem 
Cells 1994;12):205-13.
12.  Katai M, Aizawa T, Ohara N, Hiramatsu K, Hashizume 
K, Yamada T, Kitano K, Saito H, Shinoda T, Wakata S, 
Nakahata T. Acquired amegakaryocytic thrombocyto-
penic purpura with humoral inhibitory factor for mega-
karyocyte colony formation. Intern Med 1994;33:147-9.
13.   Shiozaki H, Miyawaki S, Kuwaki T, Hagiwara T, Kato T, 
Miyazaki H. Auto antibodies neutralizing thrombopoi-
etin in a patient with amegakaryocytic thrombocytope-
nic purpura. Blood 2000;95:2187-8.
14.  Kuwana M, Okazaki Y, Kajihara M, Kaburaki J, Miyazaki 
H, Kawakami Y, Ikeda Y. Autoantibody to c-Mpl (throm-
bopoietin receptor) in systemic lupus erythematosus. 
Relationship to thrombocytopenia with megakaryo-
cytic hypoplasia. Arthritis Rheum 2002;46:2148-59.
15.  Tristano AG. Acquired amegakaryocytic thrombocyto-
penic purpura: review of a not very well-defined disor-
der. Eur J Intern Med 2005;16:477-81.
16.  El Omri H, Skouri H, Kraiem I, Latiri A, Khelif A, Korbi 
S, Ennabli S. Acquired amegakaryocytic thrombocyto-
penic purpura treated with intravenous immunoglobu-
lins. Ann Med Intern (Paris) 2000;151:223-6.
17.  Quintas-Cardama A. Acquired amegakaryocytic throm-
bocytopenic purpura successfully treated with limited 
cyclosporine A therapy. Eur J Haematol 2002;69:185-6.
18.  Leach JW, Hussein KK, George JN. Acquired pure 
megakaryocytic aplasia. Report of two cases with long-
term responses to antithymocyte globulin and cyclo-
sporine. Am J Hematol 1999;62:115-7.
19.  Lonial S, Bilodeau PA, Langston AA, Lewis C, Mossavi-
Sai S, Holden JT, Waller EK. Acquired amegakaryocytic 
thrombocytopenia treated with allogeneic BMT: a case 
report and review of the literature [review]. Bone 
Marrow Transplant 1999;24:1337-41.
20.  Bulchandani D, Nachnani J, Belt R, Hinton S. Acquired 
pure megakaryocytic aplasia: report of a single case 
treated with mycophenolate mofetil. Am J Hematol 
2007;82:650-1.
Omri et al.
Acquired amegakaryocytic thrombocytopenia treated with cyclosporine Turk J Hematol 2010; 27: 289-93 293